What question did this study set out to answer?

To evaluate the effectiveness of amivantamab in patients with non-small cell lung cancer who have EGFR exon 20 mutations after platinum-based chemotherapy.

April 10, 2026Open Access

Effectiveness of amivantamab compared with real-world therapies in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations post platinum-based chemotherapy

Key Points

To evaluate the effectiveness of amivantamab in patients with non-small cell lung cancer who have EGFR exon 20 mutations after platinum-based chemotherapy.
Compared amivantamab with current real-world therapies
Analyzed outcomes from the CHRYSALIS trial
Focused on patients with EGFR ex20ins mutations
Amivantamab shows improved effectiveness compared to real-world therapies
Addresses the urgent need for treatment options in a specific patient population
Highlights the potential of amivantamab as a promising alternative post-chemotherapy

Abstract

The worse prognoses and limited treatment options for patients with advanced NSCLC harboring EGFR ex20ins from the Taiwan real-world setting indicate an urgent need for effective treatment for this population. This study showed that amivantamab, when administrated in the CHRYSALIS trial setting, represents a promising treatment option for patients compared to current real-world therapies.

Effectiveness of amivantamab compared with real-world therapies in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations post platinum-based chemotherapy

Key Points

Abstract

Cite This Study